Brazil: firms to define priority of multiple product applications
This article was originally published in Clinica
In line with its promise to shorten healthcare product approval times, Brazilian regulatory agency Anvisa has said it will allow companies with multiple applications pending to specify the order of priority in which their products should be reviewed.
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.